Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Theranos
Theranos had only $200 million of its funding left as of the end of 2016, according to a report from the Wall Street Journal, citing anonymous sources. The company previously raised nearly $900 million from investors.
During a conference call with investors last month, the company also disclosed that it didn't generate any material revenue over the last two years, and that it hasn't set aside funds to cover liabilities, according to the report.
Why it matters: The company is facing several lawsuits and investigations, so at the very least will face large legal bills, if not fines and settlements. Theranos investor Partner Fund Management and former retail partner Walgreens are suing the company, seeking to recover a total of $240 million, though Theranos has said that the lawsuits are without merit.
What's next: The company recently laid off 41% of its remaining workforce, just a few months after laying off nearly half of its employees and getting out of the lab business. The current team is focused on developing a new device it plans to sell to other clinics, though it's still awaiting regulatory approval.